[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Coronavirus, Most promising treatment so far", "description": "Well, probably. Synairgen's SNG001, Interferon beta\n\n\u00a321.29 per injection\n\nhttp://www.pharmatimes.com/news/synairgens_sng001_shows_strong_promise_in_covid-19_trial_1345119\n\nInterferon beta\n\nNaturally occurring antiviral protein\n\nCytokine\n\nInterfere with viral replication\n\nInduce fever and muscle pains (along with other cytokines)\n\nActivate immune cells, natural killer cells and macrophages\n\nReduces protein synthesis in adjacent cells\n\nActivates an enzyme to destroy RNA, further reducing protein synthesis\n\nStimulates many other interferon-stimulated genes\n\nStimulates infected cells into apoptosis\n\nKey component of human immune defence against viral infection\n\nhttps://www.sciencemediacentre.org/expert-reaction-to-announcement-by-synairgen-that-their-drug-sng001-has-had-positive-results-in-initial-trials-on-covid-19-patients/\n\nPhase 2 study\n\nInhaled interferon beta\n\nGives high local concentrations\n\nPlacebo controlled\n\nn = 101 hospitalised patients \n\nAll patients tested positive for SARS-CoV-2\n\n9 UK hospitals\n\nDiabetics\nTreatment group = 9 \nPlacebo group = 3\n\nCardiovascular disease\nTreatment group = 5\nPlacebo group = 8\n\nNow recruiting patients ill with COVID-19 in the community\n\nResults\n\n79% reduction in risk of developing severe disease\n\nRequiring ventilation or resulting in death\n\nDuring the treatment period\n\nDay one to day 16\n\nThis difference was also noted to day 28\n\nPatients who received SNG001 were more than twice as likely to recover\n\nDefined as \u2018no limitation of activities\u2019 or \u2018no clinical or virological evidence of infection\u2019\n\nMeasure of breathlessness, markedly reduced\n\nIn patients with more severe disease at time of admission\n\nSNG001 increased the likelihood of hospital discharge during the study\n\nSix days versus nine days for those receiving placebo (not significant difference)\n\nMore than twice as likely to have recovered by the end of the treatment period (strong \ntrend)\n\nSafety\n\n6% died after being randomised to placebo\n\nNo deaths in the SNG001 group\n\nProfessor Tom Wilkinson\n\nProfessor of Respiratory Medicine, University of Southampton\n\nTrial chief investigator\n\nHuge potential\n\nTo be able to restore the lung\u2019s immune response\n\nEnhancing protection\n\nAccelerating recovery\n\nCountering the impact of SARS-CoV-2 virus\n\nProfessor Stephen Holgate\n\nMedical Research Council\n\nClinical Professor of Immunopharmacology at the University of Southampton\n\nRestores the lung\u2019s ability to neutralise the virus\n\nor any mutation of the virus\n\nor co-infection with another respiratory virus such as influenza\n\nRelationship with dexamethasone and remdesivir\n\nStudy did not include patients requiring ventilatory support", "link": "https://www.youtube.com/watch?v=wqDd7ixh184", "date_published": "2020-07-21 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Coronavirus, Long term immunity more likely", "description": "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls \n\nhttps://www.nature.com/articles/s41586-020-2550-z_reference.pdf\n\nMemory T cells induced by infection\n\nFuture susceptibility and clinical severity\n\nPatients recovered from in COVID-19\n\nT cells from recovered patients recognised multiple regions of the SARS-CoV-2\n\nPatients recovered from SARS (SRS-CoV-1)\n\nSARS-recovered patients (n=23) still possess long-lasting memory T cells reactive to SARS\n\n17 years after the 2003 outbreak\n\nRobust cross-reactivity to SARS-CoV-2 NP, (structural nucleocapsid protein) \n\nSurprisingly\n\nFrequently detected SARS-CoV-2 specific T cells in individuals with no history of SARS, \n\nCOVID-19 or contact with SARS/COVID-19 patients (n=37)\n\nIn these people the T cells were active against a different part of the virus\n\nEpitope low homology to \u201ccommon cold\u201d human coronaviruses\n\nInfection with betacoronaviruses induces multispecific and long-lasting T cell immunity to the structural protein NP\n\nCows, dogs, bats, rodents\n\nUnderstanding pre-existing T cell immunity in the general population is of paramount importance for the management of the current COVID-19 pandemic", "link": "https://www.youtube.com/watch?v=R3_wSU1JnTE", "date_published": "2020-07-20 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]